Cefepime

• Description:

  Cefepime (BMY-28142) is a broad-spectrum and cross the blood-brain barrier cephalosporin. Cefepime shows antibacterial effects against both Gram-positive and Gram-negative aerobic bacteria. Cefepime induces neurotoxicity[1][2][3][4].

• Product Name Alternative:

  BMY-28142

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H312, H332

• Target:

  Antibiotic; Bacterial; Penicillin-binding protein (PBP)

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cefepime.html

• Concentration:

  10mM

• Purity:

  99.86

• Solubility:

  DMSO : 125 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

• Smiles:

  C[N+]1(CC(CS[C@]2([H])[C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)=C(C([O-])=O)N2C3=O)CCCC1

• Molecular Formula:

  C19H24N6O5S2

• Molecular Weight:

  480.56

• Precautions:

  H302, H312, H332

• References & Citations:

  [1]Yahav D, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007 May;7 (5) :338-48. |[2]Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994;47 (3) :471-505.|[3]Payne LE, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017 Nov 14;21 (1) :276. doi: 10.1186/s13054-017-1856-1. |[4]Máthé A, et al. The effect of different doses of cisplatin on the pharmacokinetic parameters of cefepime in mice. Lab Anim. 2006 Jul;40 (3) :296-300.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  β-lactam

• Citation 01:

  Antimicrob Agents Chemother. 2025 May 15:e0010225.|bioRxiv. 2024 May 10.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|Infect Genet Evol. 2025 Sep:133:105780.|Int J Antimicrob Agents. 2025 Jun 9:107551.|J Antibiot (Tokyo) . 2023 Apr;76 (4) :225-235.|J Antimicrob Chemother. 2025 Nov 5:dkaf408.|J Glob Antimicrob Resist. 2025 Jul 7:44:265-271.|Molecules. 2025 Mar 9;30 (6) :1224.|Patent. US20240209004A1.|Pharmaceutics. 2023 Nov 30;15 (12) :2705.|Vet Microbiol. 2024 May:292:110046.|Anim Dis. 2021;1 (1) :26.

• CAS Number:

  [88040-23-7]